These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 30102618)
1. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: Retraction. Cornea; 2018 Nov; 37(11):e55. PubMed ID: 30102618 [No Abstract] [Full Text] [Related]
2. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED]. Lee BA; Lee MS; Maltry AC; Hou JH Cornea; 2018 May; ():. PubMed ID: 29794826 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate. Lee BA; Lee MS; Maltry AC; Hou JH Cornea; 2021 Sep; 40(9):1197-1200. PubMed ID: 33201054 [TBL] [Abstract][Full Text] [Related]
4. Characterization and Potential Mitigation of Corneal Effects in Nonclinical Toxicology Studies in Animals Administered Depatuxizumab Mafodotin. Loberg LI; Henriques TA; Johnson JK; Miller PE; Ralston SL J Ocul Pharmacol Ther; 2022 Sep; 38(7):471-480. PubMed ID: 35537481 [No Abstract] [Full Text] [Related]
5. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167 [TBL] [Abstract][Full Text] [Related]
6. Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K Ophthalmol Ther; 2020 Dec; 9(4):913-915. PubMed ID: 32920777 [TBL] [Abstract][Full Text] [Related]
8. Confocal microscopy of central toxic keratopathy. Thornton IL; Foulks GN; Eiferman RA Cornea; 2012 Aug; 31(8):934-6. PubMed ID: 22562061 [TBL] [Abstract][Full Text] [Related]
9. Toxic keratopathy due to abuse of topical anesthetic drugs. Yeniad B; Canturk S; Esin Ozdemir F; Alparslan N; Akarcay K Cutan Ocul Toxicol; 2010 Jun; 29(2):105-9. PubMed ID: 20236030 [TBL] [Abstract][Full Text] [Related]
10. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903 [TBL] [Abstract][Full Text] [Related]
11. [Pay attention to drug induced keratopathy]. Sun XG Zhonghua Yan Ke Za Zhi; 2009 Feb; 45(2):97-9. PubMed ID: 19573325 [TBL] [Abstract][Full Text] [Related]
12. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody. Enright BP; Tornesi B; Weinbauer GF; Blaich G Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752 [TBL] [Abstract][Full Text] [Related]
13. Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2. Tian B; Wong WY; Uger MD; Wisniewski P; Chao H Front Immunol; 2017; 8():956. PubMed ID: 28871252 [TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. Sharma S; Mittapalli RK; Holen KD; Xiong H Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639 [TBL] [Abstract][Full Text] [Related]
16. Eyelid lengthening combined with penetrating keratoplasty for exposure keratopathy in Graves' ophthalmopathy--a case report. Suzuki M; Minamoto A; Ishida Y; Aoki S; Yamane K; Mishima HK Hiroshima J Med Sci; 2004 Jun; 53(2):29-31. PubMed ID: 15453395 [TBL] [Abstract][Full Text] [Related]
17. A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor. Vaidya KS; Oleksijew A; Tucker LA; Pappano WN; Anderson MG; Grinnell CM; Zhang Q; Heighton SJ; Mitten MJ; Mishra S; Palma JP; Wang J; Reilly EB; Boghaert ER Pharmacology; 2017; 100(5-6):229-242. PubMed ID: 28743107 [TBL] [Abstract][Full Text] [Related]
18. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780 [TBL] [Abstract][Full Text] [Related]
19. Metabolism and Disposition of a Novel Selective Liu H; Stresser DM; Michmerhuizen MJ; Li X; Othman AA; Reed AD; Schrimpf MR; Sydor J; Lee AJ Drug Metab Dispos; 2018 Apr; 46(4):429-439. PubMed ID: 29348125 [TBL] [Abstract][Full Text] [Related]